Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee
Journal: Osteoarthritis and Cartilage
Authors: Altman RD, Åkermark C, Beaulieu AD, Schnitzer T, on behalf of the Durolane International Study Group.
“NASHA was not superior to placebo for the primary efficacy analysis. However, these data may be confounded by the inclusion of patients with osteoarthritis at other sites, as significant benefits over placebo were found among patients with osteoarthritis confined to the knee. Future trials of osteoarthritis that examine a local therapy might need to consider restricting the study population to those patients having osteoarthritis of only the signal joint.”
A randomized saline-controlled trial of NASHA hyaluronic acid for knee osteoarthritis
Journal: Current Medical Research and Opinion
Authors: Arden NK, Åkermark C, Andersson M, Todman MG, Altman RD.
“Single-injection NASHA was well tolerated and, although there was no significant benefit versus saline control in the primary analysis, post-hoc analysis showed a statistically significant improvement in pain relief at 6 weeks among patients without clinical effusion at baseline.”
Резюме статьи доступно на сайте PubMed.gov.
NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial
Journal: Osteoarthritis and Cartilage
Authors: Leighton R, Åkermark C, Therrien R, Richardson JB, Andersson M, Todman MG, Arden NK, on behalf of the DUROLANE Study Group.
“This study shows that single-injection NASHA was well tolerated and non-inferior to MPA [methylprednisolone acetate] at 12 weeks. The benefit of NASHA was maintained to 26 weeks while that of MPA declined. An injection of NASHA at 26 weeks conferred long-term improvements without increased sensitivity or risk of complications.
Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz
Journal: Arthritis Research & Therapy
Authors: Zhang H, Zhang K, Zhang X, Zhu Z, Yan S, Sun T, Guo A, Jones J, Steen RG, Shan B, Zhang J, Lin J
“A single injection of Durolane is non-inferior to 5 injections of Artz over 18 and 26 weeks for pain, physical function, global self-assessment, and knee stiffness. Both treatments were efficacious, safe, and well tolerated.”
Полный текст статьи доступен на сайте Arthritis Research & Therapy
Knee viscosupplementation: cost-effectiveness analysis between stabilized hyaluronic acid in a single injection versus five injections of standard hyaluronic acid
Journal: International Journal of Molecular Sciences
Authors: Estades-Rubio FJ, Reyes-Martín A, Morales-Marcos V, García-Piriz M, García-Vera JJ, Perán M, Marchal JA, Montañez-Heredia E
“In conclusion, our study supports the use of the NASHA class of products in the treatment of knee OA and found a slight improvement in the economic impact on the healthcare system.”
A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis
Journal: Journal of Arthritis
Authors: McGrath AF, McGrath AM, Jessop ZM, Gandham S, Datta G, Dawson-Bowling S, Cannon SR.
“We conclude that intra-articular hyaluronic acid is a useful intervention in patients with mild to moderate osteoarthritis of the knee, can produce sustained pain relief at 6 months, and can reduce the requirement for analgesia and anti-inflammatory medication during this time.”
Factors related with the time to surgery in waiting-list patients for knee prostheses
Journal: Reumatología Clínica
Authors: Romero Jurado M, Enrique Fidalgo A, Rodríguez Villar V, Mar Medina J, Soler López B.
“Factors like a lower age of the patient and the involvement of a single joint influenced the referral of the patient to surgery. The administration of viscosupplementation delayed the time until the patient was finally referred to surgery.”
Полный текст статьи доступен на сайте Reumatologíca Cliníca.
Non-animal stabilised hyaluronic acid in the treatment of osteoarthritis of the knee. A tolerability study
Journal: Clinical Drug Investigation
Authors: Åkermark C, Berg P, Björkman A, Malm P.
“No safety concerns were raised in either the primary study or in the study extension. NASHA as an intra-articular therapy for osteoarthritis of the knee appears to have an acceptable safety profile and thus merits further investigation regarding its long-term clinical efficacy.”
Intra-articular injection of non-animal stabilised hyaluronic acid (NASHA) for osteoarthritis of the hip: A pilot study
Journal: Clinical and Experimental Rheumatology
Authors: Berg P, Olsson U.
“Our results show that a single intra-articular injection of NASHA is a well tolerated and potentially effective therapy in the treatment of hip OA. Further studies of NASHA in this setting are warranted.”
Safety, efficacy and predictive factors of efficacy of a single intra-articular injection of non-animal-stabilized-hyaluronic-acid in the hip joint: results of a standardized follow-up of patients treated for hip osteoarthritis in daily practice
Journal: Archives of Orthopaedic and Trauma Surgery
Authors: Conrozier T, Couris CM, Mathieu P, Merle-Vincent F, Piperno M, Coury F, Belin V, Tebib J, Vignon E.
“Viscosupplementation of the hip with NASHA is easily feasible in daily clinical practice, safe and well tolerated despite a frequent increase of pain the days following injection. Prospective controlled trials are needed to confirm these data and to evaluate both safety and efficacy of a second course of treatment.”
Reduction of arthrosis associated knee pain through a single intra-articular injection of synthetic hyaluronic acid
Journal: Zeitschrift für Rheumatologie
Authors: Krocker D, Matziolis G, Tuischer J, Funk J, Tohtz S, Buttgereit F, Perka C.
“We conclude that a single-injection of Durolane can reduce arthrosis associated knee pain sufficiently. Our data are comparable with those published in clinical studies using other hyaluronic acids. The effects of Durolane are delayed but more sustained compared to those found for glucocorticoids. Because of the single-injection, we see an advantage in using Durolane compared to other conventional hyaluronic acids and glucocorticoids.”
Elimination of stabilised hyaluronan from the knee joint in healthy men
Journal: Clinical Pharmacokinetics
Authors: Lindqvist U, Tolmachev V, Kairemo K, Aström G, Jonsson E, Lundqvist H.
“The elimination kinetics of 131I-labelled NASHA from the human knee joint were described by three distinct phases, with half-times of 1.5 hours, 1.5 days and 4 weeks. Most likely, the last value reflects the true half-life of NASHA following intra-articular injection since the labelling method used causes minimal modification of hyaluronan.”
Single-arm open-label study of Durolane (NASHA non-animal hyaluronic acid) for the treatment of osteoarthritis of the thumb
Journal: Open Access Rheumatology
Authors: Velasco E, Ribera MV, Pi J
“This study suggests that viscosupplementation using NASHA is effective and well tolerated in treating the symptoms of rhizarthrosis.”
Nonanimal Hyaluronic Acid for the Treatment of Ankle Osteoarthritis: A Prospective, Single-Arm Cohort Study
Journal: Journal of Foot & Ankle Surgery
Authors: Younger ASE, Penner M, Wing K, Wang Z, Wester T, Harrison A.
“In conclusion, the results of this prospective cohort study suggest that viscosupplementation with NASHA in the treatment of ankle OA holds promise. A single injection was associated with clinically meaningful reductions in pain and disability for up to 26 weeks and, although 1 participant reported pain and withdrew from the study, the procedure was generally well tolerated. Further investigation of NASHA for the treatment of ankle OA, including a large prospective cohort study and a randomized controlled trial, appear to be merited.”